Cic edizioni internazionali
Reviews in Oncology

Bevacizumab in glioblastomas: lights and shadows

Review, 123 - 133
doi: 10.11138/rio/2013.1.4.123
Tag this article
Full text PDF
Glioblastomamultiforme (GBM) is the most vascularized of all solid tumors. Several molecules governangiogenetic processes in GBM, among these the vascular endothelial growth factor (VEGF) plays a predominant role. Increasing evidence has support the capability of bevacizumab, a humanized monoclonal antibody, to inhibit the VEGF. Several clinical trials have shown an improvement in quality of life and in progression free survival of GBM patients treated by bevacizumab. Many phase II and III studies have demonstrated the importance of this drug in terms of neurological symptoms relief and rapid radiological response. Thus, in 2009, Food and Drug Administration (FDA) approved the use of bevacizumab for the treatment of recurrent GBM. However, no increase in Overall Survival (OS) has been showed and several adverse events have been related to the treatment, such as intracranial hemorrhage and venous thromboembolism.
The aim of this review is to critically evaluate the efficacy and the safety associated with bevacizumab and to identify the best strategy for its use in the management of GBM.

Vol. 3 (No. 1) 2015 January - December

  1. Pregnancy in breast cancer survivors: safety and feasibility
    Stani S.C., Sini V.
    doi: 10.11138/rio/2015.1.5.105
Last Viewed articles: la lista degli ultimi x visitati.
  1. Bevacizumab in glioblastomas: lights and shadows
    Spinelli G.P., Stati V., Prete A.A., Lo Russo G., Miele E., Sinjari M., Chiotti M.S., Ciabatta F.R., Rossi B., Tomao S.
    doi: 10.11138/rio/2013.1.4.123